Funded projects

Twelve transnational research consortia are funded under the umbrella of the NEURON JTC2009 “New Technologies”. In total, 45 research groups from ten European countries and Israel collaborate in these projects. The total funding volume of the call adds up to 10.3 million €. A variety of methodological approaches will be pursued, ranging from epigenetics to nanotechnology.

Projects and collaboration partners are shown below. Please click on “project description” to download a brief project overview. See also our related newsletter, summarizing all projects in one document.

 

Acronym

Title, Project Description, and Outcomes

Coordinator and Partners

ADtest

Role of proteases and their inhibitors in pathophysiology and diagnosis of Alzheimer Disease

 

project description (pdf, 133 KB)
outcomes (pdf, 51KB)

M. Glatzel (DE)

H. Jahn (DE),

T. Clausen (AT)

I. Ferrer (ES)

EPITHERAPY

An epigenetic approach towards the recovery of neuronal network plasticity and cognitive function in neurodegenerative disease


project description (pdf, 303 KB)
outcomes (pdf, 53 KB)

A. Fischer (DE)

A. Barco (ES)

X. Leinekugel (FR)

ERMCC-NDEG

The activity-driven ER-mitochondria Calcium Cycle (ERMCC) and protein

misfolding in neurodegenerative diseases: finding targets for therapy


project description (pdf, 130 KB)
outcomes (pdf, 55 KB)

J. Grosskreutz (DE)

B. Keller (DE)

J. Garcia-Sancho (ES)

M. T. Carri (IT)

FamPD

Identification of new genes causing familial forms of PD

 

project description (pdf, 131 KB)
outcomes (pdf, 73 KB) 

T. Gasser (DE)

N. Wood (UK)

A. Brice (FR)

Heteropark

Synthesis and validation of antiparkinsonian drugs targeting GPCR heteromers

project description (pdf, 126 KB)
outcomes (pdf, 51 KB)

R. Franco (ES)

M.-T. Armentero (IT)

C. E. Mueller (DE)

J. L. Lanciego (ES)

iPSoALS

Modelling sporadic ALS in motor neurons by genetic reprogramming of patient skin fibroblasts

 

project description (pdf, 133 KB)
outcomes (pdf, 65 KB) 

G. Haase (FR)

B. Reubinoff (IL)

P. Andersen (SE)

J. M. Heard (FR)

T. Misgeld (DE)

mGluRpatho

Group III metabotropic glutamate receptors (mGluRs): from new molecules to therapeutic development for the treatment of Parkinson’s disease

 
project description (pdf, 132 KB) 
outcomes (pdf, 53 KB)

M. Amalric (FR)

F. Acher (FR)

G. Fisone (SE)

F. Nicoletti (IT)

MIPROTRAN

Transfer of misfolded protein as a pathogenetic mechanism in neurodegenerative disease

 

project description (pdf, 136 KB)

outcomes (pdf, 75 KB)

P. Brundin (SE)

R. Melki (FR)

M. Jucker (DE)

O. Riess (DE)

nEUROsyn

Molecular mechanisms underlying synaptic dysfunction in prototypic neurodegenerative diseases related to protein misfolding

 

project description (pdf, 135 KB)
outcomes (pdf, 75 KB)

F. Tagliavini (IT)

J. R. Naranjo (ES)

G. Binetti (IT)

J.-Y. Li (SE)

PARKCDNF

Development of an experimental therapeutic strategy using the newly identified growth factor CDNF for treatment of Parkinson’s disease

 

project description (pdf, 132 KB)
outcomes (pdf, 52 KB)

K. Krieglstein (DE)

M. Saarma (FI)

E. Fuchs (DE)

R. Tuominen (FI)

O. Lindvall (SE)

PhysiolDBS

Physiological mechanisms of Deep Brain Stimulation in Parkinson’s disease

 

project description (pdf, 132 KB)
outcomes (pdf, 57 KB) 

J. Volkmann (DE)

C. Hammond (FR)

P. Winn (UK)

A. Priori (IT)

A. Schnitzler (DE)

ProGen

Protecting against neurodegeneration by somatic gene therapy

 

project description (pdf, 133 KB)
outcomes (pdf, 52 KB)

T. Arendt (DE)

J. Uney (UK)

B. Nawrot (PL)

 

 

 


top